A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Financial Summary
| Share Statistics | KYNB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $30.4 | $292.6 | 12% |
|
| Shares Out (Mil) | 4.0 | 54.4 | 12% |
|
| Institutional Ownership | 85.1% | 93.2% | 53% |
|
| Float (Mil) | 3.6 | 40.2 | 9% |
|
| Beta | 1.04 | 0.94 | 63% |
|
| Avg Daily Volume (000s) | 16 | 544 | 19% |
|
| Price Change (52-week) |
(29.2%) | 59.7% | 23% |
|
| Growth | KYNB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (48.5%) | 13.6% | 0% |
|
| Net Income (5yr) | 24.3% | (10.1%) | 79% |
|
| EPS (5yr) | 23.4% | 16.0% | 73 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.9%) | (15.6%) | 46% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 1 | 2 | |
| Current EPS | ($3.335) | ($12.410) | ($14.230) | |
| Month Ago EPS | ($3.330) | ($13.750) | ($11.437) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($3.385) | ($13.890) | ($9.730) | |
| Year/Year Chg | (212.7%) | (13.8%) | 8.7% | |
| Financials | KYNB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5 | $37 | 6% |
|
| Net Income (TTM) (Mil) | $183 | ($43) | 67% |
|
| EPS (TTM) | $45.266 | ($1.400) | 99% |
|
| Operating Cash Flow (TTM) (Mil) | ($38) | ($31) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($69) | $2 | 17% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($40) | $164 | 1% |
|
| Valuation | KYNB | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.83 | na |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | KYNB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (489.1%) | 64.2% | 0% |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | 131.3% | (47.5%) | 100% |
|
| ROE | (144.7%) | (55.0%) | 6% |
|
| Liabilities to Assets | 108.1% | 29.6% | 95% |
|
| F-Score | 6 | 3 | na |
|
Kyntra Bio, Inc. did not pass any screens on 8/21/2026.
